The Cornerstone Of Liver Disease Management Throughout The Entire Process - The Mengjianini Needle - Has Undergone A Multi-dimensional Evolution in The Modern Liver Disease Diagnosis And Treatment System.

The cornerstone of liver disease management throughout the entire process - the Mengjianini needle - has undergone a multi-dimensional evolution in the modern liver disease diagnosis and treatment system.
Key words: Jengeni liver biopsy needle for diagnosis and assessment + The core basis for liver disease staging, therapeutic effect judgment and prognosis evaluation
In the process of liver disease research moving from vague descriptions to precise staging, liver histopathology has always been the unshakable "gold standard". The Mendegani needle, as one of the preferred tools for obtaining this "gold standard" sample, has long transcended the initial diagnostic scope of merely "taking a piece of liver tissue for examination". It has deeply integrated into the entire cycle of chronic liver disease management, playing an irreplaceable role as a decision-making basis at multiple key nodes such as disease staging, treatment decision-making, efficacy assessment, prognosis judgment, and liver transplantation management.
The starting point of diagnosis: from morphological identification to etiological investigation. For cases of unexplained elevated liver enzymes, imaging abnormalities, or suspected liver diseases, the Mengerian biopsy is the ultimate means for a clear diagnosis. It can directly distinguish between viral hepatitis (characterized by interstitial inflammation, lymphocyte infiltration), autoimmune hepatitis (plasma cell infiltration, rosette formation), fatty liver disease (macronucleolar or micronucleolar steatosis), drug-induced liver injury (zoneal necrosis, eosinophil infiltration), and genetic metabolic diseases (such as copper deposition in Wilson's disease, iron deposition in hemochromatosis). For focal liver lesions, under the guidance of ultrasound or CT, the Mengerian needle can perform targeted puncture on suspicious nodules, and the obtained columnar tissue strips are of decisive value for differentiating hepatocellular carcinoma, cholangiocellular carcinoma, metastatic cancer, and benign nodules (such as focal nodular hyperplasia, adenoma). Especially in the early diagnosis of small liver cancer with low alpha-fetoprotein (AFP), the biopsy pathology is the sole basis for confirmation.
The scale of staging: "Quantitative" assessment of fibrosis and inflammatory activity. For chronic liver diseases (such as chronic hepatitis B, hepatitis C, and fatty liver), the core for determining the severity and progression risk of the disease lies in the staging of liver fibrosis and the grading of inflammatory activity. The complete tissue strips obtained by the Menegoni needle are sufficient for continuous sectioning, which can be used for the most widely used METAVIR scoring system (for hepatitis C) or the Ishak scoring system (more suitable for hepatitis B and other diseases). Pathologists evaluate the degree of fibrosis (F0-F4, where F4 indicates cirrhosis) and the degree of inflammatory activity (A0-A3) under the microscope. These "F" and "A" scores are the main basis for determining whether antiviral treatment is needed, choosing which treatment plan (such as whether to prioritize the use of potent antiviral drugs), and assessing the risk of liver cirrhosis complications. Although non-invasive tests (such as FibroScan) are convenient, their accuracy remains controversial in the intermediate stage (such as F2-F3), and ultimately, the results of Menegoni biopsy are often used as the verification and calibration benchmark.
The judge of therapeutic efficacy: Pathological confirmation of therapeutic response. After initiating antiviral treatment (such as DAA therapy for hepatitis C, nucleoside analogues for hepatitis B) or liver-protective and anti-fibrotic treatment, how can we determine if the treatment has truly been effective? The improvement in biochemical indicators (transaminases) and virological indicators (viral load) are initial evidence, but histological improvement is the more definitive endpoint of "cure" or "effectiveness". Six months or one year after the end of treatment, by conducting a second Mameni biopsy and comparing the changes in histological scores before and after treatment, one can objectively assess whether inflammation has subsided, fibrosis has reversed or stagnated. For example, after the cure of chronic hepatitis C, confirming the regression of fibrosis can greatly boost patients' confidence and change their long-term follow-up strategies. In drug clinical trials for non-alcoholic steatohepatitis (NASH), the improvement in liver histology (fatty change, ballooning change, reduction in inflammation score) is a key endpoint indicator for whether the drug can be approved.
The "monitoring device" for transplanted livers: Early diagnosis of rejection reactions and disease recurrence. In the field of liver transplantation, the Mendegani biopsy (usually performed through the transjugular approach) plays a crucial role. For patients with abnormal liver function after transplantation, the biopsy is the only reliable method for differentiating acute cellular rejection, biliary complications, drug toxicity damage, and recurrence of the original disease (such as hepatitis B, hepatitis C, liver cancer). Through regular planned biopsies (such as one year, three years, and five years after the operation), even if liver function indicators are normal, subclinical rejection or recurrence can be detected, enabling early intervention and significantly improving the long-term survival rate of the transplanted liver. This requires that the biopsy needle can safely and repeatedly obtain representative tissues, and the reliability of the Mendegani needle is fully demonstrated here.
The crystal ball of prognosis: Connecting histology with long-term clinical outcomes. A large number of long-term cohort studies have established a strong correlation between liver histopathology and patients' long-term outcomes (such as the occurrence of decompensated liver cirrhosis, hepatocellular carcinoma, and liver disease-related deaths). Specific histological features, such as bridging fibrosis (F3), cirrhosis (F4), hepatocyte ballooning degeneration, Mallory-Denk bodies, etc., are independent risk factors for predicting poor prognosis. Therefore, the information provided by a high-quality Mameni biopsy not only serves the current treatment decisions but also helps to outline the future risk profile for patients, guiding more intensive monitoring (such as the frequency of liver cancer screening) and more proactive primary prevention.
Therefore, the Mengjianini needle is no longer merely a "sampling device", but has become a core information hub throughout the entire process of "diagnosis, treatment, evaluation and management" of liver diseases. What it extracts from this silent organ of the liver is an irreplaceable "pathological code" about past damage, current activity and future risks. Interpreting this code is the cornerstone for modern hepatology to achieve individualized and precise management, and the Mengjianini needle is precisely the reliable key that has withstood the test of time to unlock this code.
Chapter Five: Intelligent Navigation and Precise Intervention - The Mengjini Needle Technique in the Absence of